Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction in Patients With Multiple Sclerosis: A Pilot Trial.
Hanne Kobberø, Jan Krhut, Peter Zvara...
https://pubmed.ncbi.nlm.nih.gov/40223778/Actively Recruiting
Led by Odense University Hospital · Updated on 2026-10-16
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness of sacral neuromodulation SNM to improve bladder function in patients with multiple sclerosis MS who have refractory neurogenic lower urinary tract dysfunction NLUTD. This randomized, multi-center, double-blinded, placebo-controlled trial aims to compare SNM against a sham procedure to see if it improves key bladder diary variables like frequency of voiding and leakages. The study also monitors bowel and sexual function changes and quality of life, reflecting the common pelvic-organ issues faced by MS patients. Participants first undergo the SNM procedure and a 3 to 4-week test period. Those showing over 50% improvement in bladder diary variables receive an implantable pulse generator IPG. After a month of optimization, participants are randomly assigned to have the IPG either turned ON active neuromodulation or OFF placebo control for a four-month randomized period. This device-based intervention is reversible and minimally invasive, with two parallel groups receiving either continuous neuromodulation or no neuromodulation. Throughout the study, participants complete evaluations at baseline, after the test period, at randomization, and at study end, over a total time frame of six months. Data collected include bladder, bowel, and sexual function assessments, patient-reported outcomes, quality of life questionnaires, and urodynamic studies. Safety and device use details are recorded. Participants will then be followed every 6 months for up to 5 years to observe longer-term effects and safety.
CONDITIONS
Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction
H
Hanne Kobberø
M
Mads H Poulsen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Odense University Hospital
Lead Sponsor
University of Copenhagen
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - 3 to 4 weeks
Participants undergo the sacral neuromodulation procedure followed by a 3 to 4-week test period to assess improvement in bladder function.
Regular monitoring visits during test period
Duration - 1 month
Participants showing over 50% improvement receive the implantable pulse generator (IPG) and undergo a month of device optimization.
Visits for device adjustment and monitoring
Duration - 4 months
Participants are randomly assigned to have the IPG turned ON (active treatment) or OFF (placebo) for four months to evaluate the effects of neuromodulation.
Monthly visits for assessment and follow-up
Duration - Up to 5 years
Participants are followed every 6 months for up to 5 years to monitor long-term effects and safety.
Biannual visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hanne Kobberø, Jan Krhut, Peter Zvara...
https://pubmed.ncbi.nlm.nih.gov/40223778/Odense University Hospital
Lead Sponsor
University of Copenhagen
Collaborating Sponsor